IPO registrations (S-1, F-1) · Registrants
60 DEGREES PHARMACEUTICALS, INC.
- SEC CIK
- 1946563 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2023-01-31, last 2025-07-07; 4 initial registrations, 6 amendments
- Outcome
- Final prospectus filed 2023-07-13; declared effective 2023-07-11
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 1025 CONNECTICUT AVENUE NW, SUITE 1000, Washington, DC 20036
- EIN
- 45-2406880
- Ticker
- SXTP, SXTPW (Nasdaq, Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- 60 DEGREES PHARMACEUTICALS, INC. on the corporate pages
On this site
- Business registration: 60 Degrees Pharmaceuticals, Inc. Fuzzy (name and state)
- Business registration: 60 DEGREES PHARMACEUTICALS, INC. Fuzzy (name and state)
- Business registration: 60 DEGREES PHARMACEUTICALS, LLC Fuzzy (name and state)
- Federal award recipient: 60 DEGREES PHARMACEUTICALS, INC. Fuzzy (name and state)
- Form D issuer: 60 DEGREES PHARMACEUTICALS, INC. EXACT (CIK (EXACT))
- Lobbying client: 60 DEGREES PHARMACEUTICALS Fuzzy (name and state)
- SEC filer: 60 DEGREES PHARMACEUTICALS, INC. EXACT (CIK (EXACT))
- Person page: Geoffrey S Dow Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer))
Filings 20
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2023-01-31 | S-1 | S-1 (registration) | 60 DEGREES PHARMACEUTICALS, INC. | 0001575872-23-000186 ↗ |
| 2023-04-03 | S-1/A | S-1/A (amendment) | 60 DEGREES PHARMACEUTICALS, INC. | 0001575872-23-000507 ↗ |
| 2023-04-28 | S-1/A | S-1/A (amendment) | 60 DEGREES PHARMACEUTICALS, INC. | 0001575872-23-000644 ↗ |
| 2023-05-19 | S-1/A | S-1/A (amendment) | 60 DEGREES PHARMACEUTICALS, INC. | 0001575872-23-000790 ↗ |
| 2023-06-01 | S-1/A | S-1/A (amendment) | 60 DEGREES PHARMACEUTICALS, INC. | 0001575872-23-000882 ↗ |
| 2023-06-08 | S-1/A | S-1/A (amendment) | 60 DEGREES PHARMACEUTICALS, INC. | 0001575872-23-000911 ↗ |
| 2023-07-11 | EFFECT | EFFECT (declared effective) | 60 DEGREES PHARMACEUTICALS, INC. | 9999999995-23-002054 ↗ |
| 2023-07-13 | 424B4 | 424B4 (final prospectus) | 60 DEGREES PHARMACEUTICALS, INC. | 0001575872-23-001147 ↗ |
| 2024-01-22 | S-1 | S-1 (registration) | 60 DEGREES PHARMACEUTICALS, INC. | 0001213900-24-005285 ↗ |
| 2024-01-29 | EFFECT | EFFECT (declared effective) | 60 DEGREES PHARMACEUTICALS, INC. | 9999999995-24-000246 ↗ |
| 2024-01-31 | 424B4 | 424B4 (final prospectus) | 60 DEGREES PHARMACEUTICALS, INC. | 0001213900-24-008068 ↗ |
| 2024-07-18 | EFFECT | EFFECT (declared effective) | 60 DEGREES PHARMACEUTICALS, INC. | 9999999995-24-002202 ↗ |
| 2024-09-30 | EFFECT | EFFECT (declared effective) | 60 DEGREES PHARMACEUTICALS, INC. | 9999999995-24-003042 ↗ |
| 2025-02-14 | S-1 | S-1 (registration) | 60 DEGREES PHARMACEUTICALS, INC. | 0001213900-25-014334 ↗ |
| 2025-03-27 | S-1/A | S-1/A (amendment) | 60 DEGREES PHARMACEUTICALS, INC. | 0001013762-25-003353 ↗ |
| 2025-04-02 | EFFECT | EFFECT (declared effective) | 60 DEGREES PHARMACEUTICALS, INC. | 9999999995-25-000945 ↗ |
| 2025-07-07 | S-1 | S-1 (registration) | 60 DEGREES PHARMACEUTICALS, INC. | 0001213900-25-061842 ↗ |
| 2025-07-15 | EFFECT | EFFECT (declared effective) | 60 DEGREES PHARMACEUTICALS, INC. | 9999999995-25-002259 ↗ |
| 2025-07-16 | 424B4 | 424B4 (final prospectus) | 60 DEGREES PHARMACEUTICALS, INC. | 0001213900-25-064472 ↗ |
| 2026-08-25 | EFFECT | EFFECT (declared effective) | 60 DEGREES PHARMACEUTICALS, INC. | 9999999995-26-002759 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Allen Charles W | Director | 2 | 2023–2024 | ||
| DOW GEOFFREY S | Director,Officer; Director,Officer,TenPercentOwner | CEO and President; President and CEO | 13 | 2023–2026 | person page Fuzzy |
| FIELD PAUL | Director | 2 | 2023–2024 | ||
| Florida State University Research Foundation Inc. | TenPercentOwner | 1 | 2023 | ||
| KENTUCKY TECHNOLOGY INC. | TenPercentOwner | 1 | 2023 | ||
| MILLER TYRONE | Officer | CFO; Chief Financial Officer | 5 | 2023–2025 | |
| SMITH BRYAN LEE | Officer | Chief Medical Officer | 1 | 2023 | |
| TOOVEY STEPHEN | Director | 2 | 2023–2024 | ||
| XU CHERYL | Director | 6 | 2023–2025 | ||
| Knight Therapeutics Inc | Other; TenPercentOwner | 3 | 2023–2026 | ||
| KNIGHT THERAPEUTICS INTERNATIONAL SA | Other; TenPercentOwner | 2 | 2023–2024 | ||
| Landon Kristen | Officer | Chief Operating Officer | 3 | 2025 | |
| Francois Eric | Director | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2025-02-12 | 60 DEGREES PHARMACEUTICALS, INC. | Pharmaceuticals | $1,075,003 | $1,075,003 | 4 | 1 |
| 2025-02-11 | 60 DEGREES PHARMACEUTICALS, INC. | Pharmaceuticals | $1,043,002 | $1,043,002 | 4 | 1 |
| 2023-05-24 | 60 DEGREES PHARMACEUTICALS, INC. | Pharmaceuticals | Indefinite | $1,755,000 | 10 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.